Biotechnology Assets (XMAD:BST) Retained Earnings: €-25.48 Mil (As of Dec. 2025)


XMAD:BST Biotechnology Assets SA XMAD:BST
22 GF Score
Price €0.21
GF Value €0.30
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Biotechnology Assets Retained Earnings?

Biotechnology Assets XMAD:BST -1.87% 22 Retained Earnings is €-25.48 Mil as of Dec. 2025. GuruFocus rates XMAD:BST with a GF Score™ of 22/100 and a GF Value™ of €0.30 (Possible Value Trap). The stock has 3 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Biotechnology Assets's retained earnings for the quarter that ended in Dec. 2025 was €-25.48 Mil.

Biotechnology Assets's quarterly retained earnings declined from Dec. 2024 (€-23.57 Mil) to Jun. 2025 (€-24.40 Mil) and declined from Jun. 2025 (€-24.40 Mil) to Dec. 2025 (€-25.48 Mil).

Biotechnology Assets's annual retained earnings declined from Dec. 2023 (€-20.65 Mil) to Dec. 2024 (€-23.57 Mil) and declined from Dec. 2024 (€-23.57 Mil) to Dec. 2025 (€-25.48 Mil).


Biotechnology Assets  (XMAD:BST) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Biotechnology Assets Retained Earnings Historical Data

* Premium members only.

The historical data trend for Biotechnology Assets's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biotechnology Assets Retained Earnings Chart

Biotechnology Assets Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -19.86 -22.22 -20.65 -23.57 -25.48

Biotechnology Assets Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -20.65 -22.32 -23.57 -24.40 -25.48
XMAD:BST
22GF Score
Biotechnology Assets SA XMAD:BST
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biotechnology Assets Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of €-25.48 Mil mean?
Biotechnology Assets (XMAD:BST) has a Retained Earnings of €-25.48 Mil as of Dec. 2025. Retained earnings is the amount of net income not issued to shareholders. View historical data on Biotechnology Assets and its competitors.
Is Biotechnology Assets' Retained Earnings too high?
Biotechnology Assets' current Retained Earnings is €-25.48 Mil. Overall, Biotechnology Assets has a GF Score™ of 22/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Biotechnology Assets' Retained Earnings compare to VRTX and REGN?
Biotechnology Assets' Retained Earnings of €-25.48 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Biotechnology Assets and its competitors. Biotechnology Assets's current Retained Earnings is €-25.48 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biotechnology Assets stock overvalued right now?
Based on GuruFocus' analysis, Biotechnology Assets (XMAD:BST) is currently considered Possible Value Trap. The stock's GF Value™ is €0.30, compared to a current price of €0.21 — trading 30% below its estimated fair value. The current Retained Earnings is €-25.48 Mil. Biotechnology Assets' overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Biotechnology Assets (XMAD:BST), the current Retained Earnings is €-25.48 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biotechnology Assets (XMAD:BST) Overvalued in 2026?

Based on GuruFocus' analysis, Biotechnology Assets stock appears to be undervalued. The current stock price of €0.21 is trading 30% below its estimated GF Value™ of €0.30. GuruFocus considers Biotechnology Assets to be Possible Value Trap.

Key valuation signals for XMAD:BST:

  • Retained Earnings: €-25.48 Mil
  • GF Value™: €0.30 vs. price of €0.21 (30% below fair value)
  • GF Score™: 22/100 with 3 warning signs

No single metric tells the full story. See the XMAD:BST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Biotechnology Assets Business Description

Address Avenida del Desarrollo Tecnologico, No. 11, Scientific and Technological Park, Jerez de la Frontera, ESP, 11591
Biotechnology Assets SA is a clinical-stage biopharmaceutical company developing and producing biological products for the pharmaceutical and veterinarian sectors. It specializes in the prevention and treatment of niche diseases, such as orphan disease, antigens for new-generation vaccines, feed additives, and probiotics. Adl Bionatur offers a portfolio of non-therapeutic and therapeutic products to tier 1 and tier 2 animal health companies. The company's pipeline products include BNT006, BNT007, BNT010, and others.
22GF Score

Get the complete analysis for XMAD:BST

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.21
Price
€0.30
GF Value